


RN 396718-71-1 HCAPLUS

CN .beta.-D-Ribofuranuronamide, 1-[6-[(10-aminodecyl)amino]-9H-purin-9-yl]-1-deoxy-N-ethyl-2,3-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 396718-75-5 HCAPLUS


CN .beta.-D-Ribofuranuronamide, 1-deoxy-N-ethyl-2,3-O-(1-methylethylidene)-1-[6-[[2-[(7-nitro-2,1,3-benzoxadiazol-4-yl)amino]ethyl]amino]-9H-purin-9-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 396718-77-7 HCAPLUS

CN .beta.-D-Ribofuranuronamide, 1-deoxy-N-ethyl-2,3-O-(1-methylethylidene)-1-[6-[[4-[(7-nitro-2,1,3-benzoxadiazol-4-yl)amino]butyl]amino]-9H-purin-9-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



RN 396718-79-9 HCAPLUS  
 CN .beta.-D-Ribofuranuronamide, 1-deoxy-N-ethyl-2,3-O-(1-methylethylidene)-1-[6-[[6-[(7-nitro-2,1,3-benzoxadiazol-4-yl)amino]hexyl]amino]-9H-purin-9-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



RN 396718-81-3 HCAPLUS  
 CN .beta.-D-Ribofuranuronamide, 1-deoxy-N-ethyl-2,3-O-(1-methylethylidene)-1-[6-[[8-[(7-nitro-2,1,3-benzoxadiazol-4-yl)amino]octyl]amino]-9H-purin-9-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



RN 396718-83-5 HCAPLUS  
 CN .beta.-D-Ribofuranuronamide, 1-deoxy-N-ethyl-2,3-O-(1-methylethylidene)-1-[6-[[10-[(7-nitro-2,1,3-benzoxadiazol-4-yl)amino]decyl]amino]-9H-purin-9-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

NO<sub>2</sub>

REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L35 ANSWER 40 OF 63 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1989:193332 HCAPLUS

DOCUMENT NUMBER: 110:193332

TITLE: Preparation of adenosine-5'-carboxamide derivatives as adenosine-2 receptor agonists, antipsychotics, and antihypertensives and pharmaceutical compositions containing them

INVENTOR(S): Hutchison, Alan J.

PATENT ASSIGNEE(S): Ciba-Geigy A.-G., Switz.

SOURCE: Eur. Pat. Appl., 17 pp.

CODEN: EPXXDW

DOCUMENT TYPE:

Patent

LANGUAGE:

English


FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 277917	A2	19880810	EP 1988-810050	19880129
EP 277917	A3	19900328		

R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE

FI 8800405	A	19880805	FI 1988-405	19880129
JP 63201196	A2	19880819	JP 1988-21410	19880202
DD 284679	A5	19901121	DD 1988-312611	19880202
DK 8800544	A	19880805	DK 1988-544	19880203
NO 8800469	A	19880805	NO 1988-469	19880203
AU 8811233	A1	19880818	AU 1988-11233	19880203
HU 46334	A2	19881028	HU 1988-509	19880203
HU 199155	B	19900129		
ZA 8800755	A	19891025	ZA 1988-755	19880203
PRIORITY APPLN. INFO.:		US 1987-11169		19870204
OTHER SOURCE(S):		MARPAT 110:193332		
GI				



AB The title compds. [I; R2 = H, alkyl, aralkyl; R3 = H, OH; R5 = NRR1 where R = H, alkyl and R1 = cycloalkyl, cycloalkylalkyl, 2-norbornanyl, etc.; R6 = R4NHCO where R4 = H, alkyl, aralkyl, cycloalkyl, hydroxyalkyl] (II) and their pharmaceutically acceptable salts, useful as adenosine-2 receptor agonists, antipsychotics, antithrombotics, and antihypertensives, are prepd. A mixt. of 2-chloro-2',3'-O-isopropylideneadenosine-5'-N-ethylcarboxamide and 2-phenethylamine was heated at 130.degree. for 2 h to give 2-(2-phenethylamino)-2',3'-O-isopropylideneadenosine-5'-N-ethylcarboxamide, which was heated with 1N HCl at 65.degree. for 1 h to give 2-(2-phenethylamino)-5'-N-ethylcarboxamide (III). In vivo studies of the adenosine-2 receptor agonistic activity of II using spontaneously hypertensive rats showed that II effectively lowered the blood pressure without any significant effect on the heart rate. One thousand tablets were prepd. from III 100.00, lactose 2400.00, corn starch 125.00, polyethyleneglycol 6000 150.00, Mg stearate 40.00 g, and water q.s.

IT 120225-76-5P 120225-77-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(prepn. and reaction of, in prepn. of adenosinecarboxamide derivs. as CNS and cardiovascular agents)

RN 120225-76-5 HCAPLUS

CN Benzenepropanoic acid, 4-[2-[[6-amino-9-[N-ethyl-2,3-O-(1-methylethylidene)-.beta.-D-ribofuranuronamidosyl]-9H-purin-2-yl]amino]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

—OBu-t

RN 120225-77-6 HCAPLUS

CN .beta.-D-Ribofuranuronamide, 1-[6-amino-2-[(2-phenylethyl)amino]-9H-purin-9-yl]-1-deoxy-N-ethyl-2,3-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 120225-75-4 120225-76-5

RL: RCT (Reactant); RACT (Reactant or reagent)


(reaction of, in prepn. of adenosinecarboxamide derivs. as CNS and cardiovascular agents)



RN 120225-75-4 HCAPLUS

CN .beta.-D-Ribofuranuronamide, 1-(6-amino-2-chloro-9H-purin-9-yl)-1-deoxy-N-ethyl-2,3-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 120225-76-5 HCAPLUS

CN Benzenepropanoic acid, 4-[2-[[6-amino-9-[N-ethyl-2,3-O-(1-methylethylidene)-.beta.-D-ribofuranuronamidosyl]-9H-purin-2-yl]amino]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

—OBu-t

L35 ANSWER 41 OF 63 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1989:24223 HCAPLUS

DOCUMENT NUMBER: 110:24223

TITLE: Conformational analysis of 8-substituted  
isopropylidene derivatives of adenosine-5'-carboxylic  
acid

AUTHOR(S): Timoshchuk, V. A.; Ermolenko, T. M.; Akhrem, A. A.

CORPORATE SOURCE: Beloruss. Inst. Epidemiol. Mikrobiol., Minsk, USSR

SOURCE: Zhurnal Organicheskoi Khimii (1988), 24(6), 1214-20

CODEN: ZORKAE; ISSN: 0514-7492

DOCUMENT TYPE: Journal

LANGUAGE: Russian

AB NMR data confirms that for 2',3'-O-isopropylidene derivs. of adenosine 5'-carboxylic acid the most probable conformation is C4'-endo, O4'-exo, and C1'-endo. Compds. of this series are characterized principally by a syn-conformation of the heterocycle around the N-glycosidic bond relative to the ribose fragment of the mols. CD data confirmed that conformations are stabilized by a spatial convergence of the N3 heterocyclic atom and the carboxyl group.

IT 101966-36-3 101966-40-9 101966-46-5


RL: PRP (Properties)

(conformation of, NMR and CD in relation to)

RN 101966-36-3 HCAPLUS

CN .beta.-D-Ribofuranuronamide, 1-deoxy-1-(6,8-diamino-9H-purin-9-yl)-N-ethyl-  
2,3-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 101966-40-9 HCAPLUS

CN .beta.-D-Ribofuranuronamide, 1-[6-amino-8-(methylamino)-9H-purin-9-yl]-1-deoxy-N-methyl-2,3-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 101966-46-5 HCAPLUS

CN .beta.-D-Ribofuranuronamide, 1-[6-amino-8-(dimethylamino)-9H-purin-9-yl]-1-deoxy-N-methyl-2,3-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L35 ANSWER 42 OF 63 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1986:627200 HCAPLUS

DOCUMENT NUMBER: 105:227200

TITLE: Synthesis of uronic acid nucleosides. II. Synthesis of 8-substituted adenosine-5'-carboxamides

AUTHOR(S): Akhrem, A. A.; Ermolenko, T. M.; Timoshchuk, V. A.

CORPORATE SOURCE: Beloruss. Nauchno-Issled. Inst. Epidemiol. Mikrobiol., Minsk, USSR


SOURCE: Zhurnal Organicheskoi Khimii (1985), 21(8), 1800-5

CODEN: ZORKAE; ISSN: 0514-7492

DOCUMENT TYPE: Journal

LANGUAGE: Russian

GI



AB Amides of 8-substituted adenosine-5'-carboxylic acid were prepd. Starting from the Me ester of 8-bromo-2',3'-O-isopropylideneadenosine-5'-carboxylate and the Et ester of 8-bromoadenosine-5'-carboxylate were obtained the amide, methylamide, dimethylamide, and the ethylamide of the corresponding acid, which contained bromo-, amino, methylamino-, dimethylamino-, ethylamino-, and mercapto groups in position 8 of the adenine base. Thus, treating adenosine I (R = OMe, X = Br) with NH<sub>3</sub> in MeOH at 18-25.degree. gave 82% I (R = NH<sub>2</sub>, X = Br). The selectivity of primary and secondary amines, on the ester group and 8-bromoadenine residue was demonstrated.


IT 101966-40-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(prepn. and hydrolysis of)

RN 101966-40-9 HCAPLUS

CN .beta.-D-Ribofuranuronamide, 1-[6-amino-8-(methylamino)-9H-purin-9-yl]-1-deoxy-N-methyl-2,3-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 101966-36-3P 101966-46-5P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of)

RN 101966-36-3 HCAPLUS

CN .beta.-D-Ribofuranuronamide, 1-deoxy-1-(6,8-diamino-9H-purin-9-yl)-N-ethyl-2,3-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 101966-46-5 HCAPLUS

CN .beta.-D-Ribofuranuronamide, 1-[6-amino-8-(dimethylamino)-9H-purin-9-yl]-1-deoxy-N-methyl-2,3-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L35 ANSWER 43 OF 63 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1984:56841 HCAPLUS

DOCUMENT NUMBER: 100:56841

TITLE: Fibrinolytic formulations containing adenosine derivatives

PATENT ASSIGNEE(S): Tanabe Seiyaku Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 3 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent


LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	-----	-----	-----	-----

19820407  
19820407




AB Formulations contg. I (R1 and R2 = propionyl or R1 + R2 = methoxyethylidene) activate fibrinolysis. Thus, 2',3'-O-dipropionyladenosine-5'-carboxylic acid butylamide(I) [88480-43-7] 70, D-mannitol 73, and corn starch 50 g were mixed using 5 g hydroxypropyl cellulose as binder, granulated, combined with 2 g Mg stearate, and made into tablets. I was prepd. by the acylation of adenosine-5'-carboxylic acid butylamide [35788-23-9] with propionic anhydride.

IT **62622-82-6P**  
RL: PREP (Preparation)  
(prepn. of, for fibrinolysis activation)

RN 62622-82-6 HCAPLUS  
CN .beta.-D-Ribofuranuronamide, 1-(6-amino-9H-purin-9-yl)-N-butyl-1-deoxy-2,3-O-(1-methoxyethylidene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L35 ANSWER 44 OF 63 HCAPLUS COPYRIGHT 2003 ACS  
ACCESSION NUMBER: 1984:26035 HCAPLUS  
DOCUMENT NUMBER: 100:26035  
TITLE: Fibrinolytic formulations containing adenosine  
derivatives  
PATENT ASSIGNEE(S): Tanabe Seiyaku Co., Ltd., Japan  
SOURCE: Jpn. Kokai Tokkyo Koho, 8 pp.

DOCUMENT TYPE:

CODEN: JKXXAF

LANGUAGE:


Patent

FAMILY ACC. NUM. COUNT: 1

Japanese

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 58174323	A2	19831013	JP 1982-58506	19820407
PRIORITY APPLN. INFO.: GI			JP 1982-58506	19820407



AB Fibrinolytic formulations contain I (R1 and R2 = H, alkanoyl, etc.; R3 = C1-3 alkylamino, alkenylamino, etc.). Thus, adenosine-5'-carboxylic acid cyclohexylamide [35788-32-0] was treated with Me orthoacetate [56893-90-4] to give 2',3'-O-methoxyethylideneadenosine-5'-carboxylic acid cyclohexylamide (II) [88255-85-0]. Tablets contg. 1% I were described. The min. effective oral dose for the hemolytic activity of II in rats was 30 mg/kg.


IT 62622-78-0P 88255-90-7P


RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. and fibrinolytic activity of)

RN 62622-78-0 HCAPLUS

CN .beta.-D-Ribofuranuronamide, 1-(6-amino-9H-purin-9-yl)-1-deoxy-N-ethyl-2,3-O-(1-methoxyethylidene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 88255-90-7 HCAPLUS

CN .beta.-D-Ribofuranuronamide, 1-(6-amino-9H-purin-9-yl)-1-deoxy-2,3-O-(1-methoxyethylidene)-N-2-propenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L35 ANSWER 45 OF 63 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1980:215696 HCAPLUS

DOCUMENT NUMBER: 92:215696

TITLE: N1,N6-Ethenoadenosine-5'-(N-ethyl carboxamide)

AUTHOR(S): Prasad, Raj Nandan; Tietje, Karin

CORPORATE SOURCE: Org. Chem. Res., Abbott Lab., Ltd., Montreal, QC, H4P 1A5, Can.

SOURCE: Nucl. Acid Chem. (1978), Volume 2, 701-7. Editor(s): Townsend, Leroy B.; Tipson, R. Stuart. Wiley: New York, N. Y.


CODEN: 42TBAU

DOCUMENT TYPE: Conference

LANGUAGE: English

GI





AB Ethenoadenosine I was prepd. by cyclization of adenosine II with ClCH<sub>2</sub>CHO. II was prepd. from acid III by 3 methods, e.g., by sequential chlorination with SOCl<sub>2</sub>, amidation with EtNH<sub>2</sub>, and deisopropylidenation.


IT 39491-53-7P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. and deisopropylidenation of)

RN 39491-53-7 HCAPLUS

CN .beta.-D-Ribofuranuronamide, 1-(6-amino-9H-purin-9-yl)-1-deoxy-N-ethyl-2,3-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L35 ANSWER 60 OF 63 HCAPLUS COPYRIGHT 2003 ACS  
 ACCESSION NUMBER: 1976:59956 HCAPLUS  
 DOCUMENT NUMBER: 84:59956  
 TITLE: Adenosine-5'-carboxylic acid amides  
 INVENTOR(S): Stein, Herman Hal; Prasad, Raj N.  
 PATENT ASSIGNEE(S): Abbott Laboratories, USA  
 SOURCE: U.S., 7 pp. Division of U.S. 3,864,483.  
 CODEN: USXXAM  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 5

## PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3914415	A	19751021	US 1974-492950	19740730
US 4029884	A	19770614	US 1972-236980	19720322
US 3864483	A	19750204	US 1973-370084	19730614
PRIORITY APPLN. INFO.:			US 1971-125893	19710318
			US 1972-236980	19720322
			US 1973-370084	19730614


- GI For diagram(s), see printed CA Issue.
- AB I (e.g., R1 = H, R2 = H, adamantyl, cyclopropyl, Et, PhOCH2CH2, allyl, 2,6-Me2C6H3, HOCH2CH2; R1 = R2 = allyl) (34 compds.), possessing cardiovascular and antiinflammatory activities, were prepd. by treatment of 2',3'-O-isopropylideneadenosine-5'-carboxylic acid chloride with R1R2NH followed by hydrolysis with 1N HCl.
- IT 39491-51-5P 39491-53-7P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (prepn. and deblocking of)
- RN 39491-51-5 HCAPLUS
- CN .beta.-D-Ribofuranuronamide, 1-(6-amino-9H-purin-9-yl)-1-deoxy-N-methyl-2,3-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



- RN 39491-53-7 HCAPLUS
- CN .beta.-D-Ribofuranuronamide, 1-(6-amino-9H-purin-9-yl)-1-deoxy-N-ethyl-2,3-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 58048-27-4P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of)

RN 58048-27-4 HCAPLUS

CN .beta.-D-Ribofuranuronamide, 1-(6-amino-9H-purin-9-yl)-1-deoxy-2,3-O-(1-methylethylidene)-N-2-propenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L35 ANSWER 61 OF 63 HCAPLUS COPYRIGHT 2003 ACS  
 ACCESSION NUMBER: 1976:44606 HCAPLUS  
 DOCUMENT NUMBER: 84:44606  
 TITLE: Compounds for increasing coronary partial pressure of oxygen in mammals  
 INVENTOR(S): Stein, Herman Hal; Prasad, Raj N.  
 PATENT ASSIGNEE(S): Abbott Laboratories, USA  
 SOURCE: U.S., 7 pp. Division of U.S. 3,864,483.  
 CODEN: USXXAM  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 5  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	-----	-----	-----	-----

US 3914414	A	19751021	US 1974-492949	19740730
US 4029884	A	19770614	US 1972-236980	19720322
US 3864483	A	19750204	US 1973-370084	19730614
US 3966917	A	19760629	US 1975-590548	19750626

PRIORITY APPLN. INFO.:

US 1971-125893	19710318
US 1972-236980	19720322
US 1973-370084	19730614
US 1974-492949	19740730

AB Adenosine-5'-carboxamides, useful as antihypertensive agents, were prepd. by treating 2',3'-O-isopropylideneadenosine-5'-carbonyl chloride (I) with amines followed by acid hydrolysis. Thus, I with NH<sub>3</sub> 2 hr at -50.degree. gave 55% 2',3'-O-isopropylideneadenosine-5'-carboxamide (II). Treatment of II with 1N HCl at 60-70.degree. for 45 min gave adenosine-5'-carboxamide.

IT 57872-94-3P 57872-95-4P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. and antihypertensive activity of)

RN 57872-94-3 HCAPLUS

RN 57872-95-4 HCAPLUS

L35 ANSWER 62 OF 63 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1975:156656 HCAPLUS

DOCUMENT NUMBER: 82:156656

TITLE: 1,N6-Etheno-5'-adenosine carboxamides

INVENTOR(S): Prasad, Raj N.; Garmaise, David L.

PATENT ASSIGNEE(S): Abbott Laboratories, USA

SOURCE: U.S., 3 pp.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 3830796	A	19740820	US 1972-317326	19721221
US 3931401	A	19760106	US 1974-472029	19740521
			US 1972-317326	19721021

PRIORITY APPLN. INFO.:

GI For diagram(s), see printed CA Issue.

AB Adenosines (I; R = Et, allyl, cyclobutyl), useful as antianginals and antihypertensives, were prepd. Thus, 2',3'-O-isopropylideneadenosine 5'-carboxylic acid chloride was treated with EtNH<sub>2</sub> at -50 to -35.degree. to give the 5'-(N-ethylcarboxamide) which, treated 1 hr with 1N HCl, gave adenosine 5'-(N-ethylcarboxamide) II. Treatment of II with ClCH<sub>2</sub>CHO gave I (R = Et). The allyl and cyclobutyl derivs. were similarly prepd.


IT 39491-53-7P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of)

RN 39491-53-7 HCAPLUS

CN .beta.-D-Ribofuranuronamide, 1-(6-amino-9H-purin-9-yl)-1-deoxy-N-ethyl-2,3-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L35 ANSWER 63 OF 63 HCAPLUS COPYRIGHT 2003 ACS  
 ACCESSION NUMBER: 1973:16454 HCAPLUS  
 DOCUMENT NUMBER: 78:16454  
 TITLE: Adenosine-5'-carboxamides  
 INVENTOR(S): Stein, Herman Hal; Prasad, Raj Nandan  
 PATENT ASSIGNEE(S): Abbott Laboratories  
 SOURCE: Ger. Offen., 12 pp.  
 CODEN: GWXXBX  
 DOCUMENT TYPE: Patent  
 LANGUAGE: German  
 FAMILY ACC. NUM. COUNT: 5  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2213180	A	19720928	DE 1972-2213180	19720317
CA 1019727	A1	19771025	CA 1972-135283	19720222
GB 1386656	A	19750312	GB 1972-8446	19720223
ZA 7201222	A	19721129	ZA 1972-1222	19720224
CH 551446	A	19740715	CH 1972-3873	19720316
FR 2130364	A5	19721103	FR 1972-9349	19720317
SE 405363	C	19790315	SE 1972-3515	19720317
SE 405363	B	19781204		

PRIORITY APPLN. INFO.: US 1971-125893 19710318  
 GI For diagram(s), see printed CA Issue.  
 AB Four title compds. (I, R = H; R1 = NH2, NHMe, NMe2, and NHEt), useful in the treatment of angina pectoris and circulatory disturbances and as antihypertensives, were prepd. Chlorination of I (RR = CMe2, R1 = OH) with SOCl2 to give I (RR = CMe2, R1 = Cl), followed by treatment with amines, R1H, and hydrolysis with N HCl gave the corresponding title compd.  
 IT 39491-51-5P 39491-53-7P  
 RL: SPN (Synthetic preparation); PREP (Preparation) (prepn. of)  
 RN 39491-51-5 HCAPLUS  
 CN .beta.-D-Ribofuranuronamide, 1-(6-amino-9H-purin-9-yl)-1-deoxy-N-methyl-2,3-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 39491-53-7 HCAPLUS

CN .beta.-D-Ribofuranuronamide, 1-(6-amino-9H-purin-9-yl)-1-deoxy-N-ethyl-2,3-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



=&gt; d que l21

L1

STR



## NODE ATTRIBUTES:

NSPEC IS RC AT 18

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

## GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED


NUMBER OF NODES IS 18

## STEREO ATTRIBUTES: NONE

L2 3214 SEA FILE=REGISTRY SSS FUL L1

L20

STR



## NODE ATTRIBUTES:

CONNECT IS E2 RC AT 9

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

## GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED  
NUMBER OF NODES IS 36.

STEREO ATTRIBUTES: NONE


L21 0 SEA FILE=REGISTRY SUB=L2 SSS FUL L20



=&gt; d que 129

L1

STR



## NODE ATTRIBUTES:

NSPEC IS RC AT 18  
 DEFAULT MLEVEL IS ATOM  
 DEFAULT ECLEVEL IS LIMITED

## GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED  
 NUMBER OF NODES IS 18

## STEREO ATTRIBUTES: NONE

L2 3214 SEA FILE=REGISTRY SSS FUL L1  
 L22 36416 SEA FILE=HCAPLUS ABB=ON PLU=ON HYPERTENSION/CT  
 L25 5576 SEA FILE=HCAPLUS ABB=ON PLU=ON ISCHEMIA+OLD/CT  
 L26 2613 SEA FILE=HCAPLUS ABB=ON PLU=ON ANTI-ISCHEMIC AGENTS/CT  
 L27 4987 SEA FILE=HCAPLUS ABB=ON PLU=ON VASODILATION/CT  
 L28 8845 SEA FILE=HCAPLUS ABB=ON PLU=ON VASODILATORS/CT  
 L29 39 SEA FILE=HCAPLUS ABB=ON PLU=ON L2 AND (L22 OR HYPERTENS? OR  
 L25 OR L26 OR ISCHEM? OR L27 OR L28 OR VASODIL? OR SYMPATHET?(2  
 A)BLOCK? OR PROPHYLACT?)

=&gt; d ibib abs hitstr 129 1-39

L29 ANSWER 1 OF 39 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:332678 HCAPLUS

DOCUMENT NUMBER: 136:350561

TITLE: Use of P2Y12 receptor antagonists as platelet aggregation inhibitors

INVENTOR(S): Boyer, Jose L.; Olins, Gillian M.; Yerxa, Benjamin R.; Douglass, James G.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 43 pp., Cont.-in-part of U. S. Ser. No. 643,138.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002052337	A1	20020502	US 2001-934970	20010821
US 2002128224	A1	20020912	US 2002-87551	20020227
US 2003008834	A1	20030109	US 2002-82998	20020227
PRIORITY APPLN. INFO.:			US 2000-643138	A2 20000821
			US 2001-934970	A2 20010821

OTHER SOURCE(S): MARPAT 136:350561

AB The invention discloses a method of preventing or treating diseases or conditions assocd. with platelet aggregation and treating thrombosis. The method involves administering to a subject a pharmaceutical compn. comprising a therapeutic effective amt. of P2Y12 receptor antagonist compd., to bind the P2Y12 receptors on platelets and inhibit ADP-induced platelet aggregation. The P2Y12 receptor antagonist compds. disclosed include mononucleoside polyphosphates and dinucleoside polyphosphates.

IT 401619-32-7 401619-52-1 401619-57-6

401620-06-2 420131-31-3 420131-40-4


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(P2Y12 receptor antagonists, as platelet aggregation inhibitors)

RN 401619-32-7 HCAPLUS

CN Adenosine 5'-(trihydrogen diphosphate), 2',3'-O-(2-phenylethylidene)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 401619-52-1 HCAPLUS


CN Adenosine 5'-(pentahydrogen tetraphosphate), 2',3'-O-(2-phenylethylidene)-, P'''-fwdarw.5'-ester with uridine (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 401619-57-6 HCAPLUS  
 CN Adenosine 5'-(pentahydrogen tetraphosphate), 2',3'-O-(2-phenylethylidene)-  
 , P'''-fwdarw.5'-ester with 2',3'-O-(2-phenylethylidene)uridine (9CI) (CA  
 INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B


Ph

PAGE 2-A



RN 401620-06-2 HCAPLUS  
CN Adenosine, N-[2-(methylthio)ethyl]-2',3'-O-(2-phenylethylidene)-2-[(3,3,3-trifluoropropyl)thio]-, 5'-[hydrogen (difluorophosphonomethyl)phosphonate] (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 420131-31-3 HCAPLUS


CN Adenosine 5'-(pentahydrogen tetraphosphate), 2',3'-O-(2-phenylethylidene)-, P'''-fwdarw.5'-ester with adenosine (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 420131-40-4 HCAPLUS


CN Adenosine 5'-(pentahydrogen tetraphosphate), N-[2-(methylthio)ethyl]-2',3'-O-(2-phenylethylidene)-2-[(3,3,3-trifluoropropyl)thio]-, P'''-fwdarw.5'-ester with 2',3'-O-(2-phenylethylidene)adenosine (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



L29 ANSWER 2 OF 39 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2002:271942 HCAPLUS

DOCUMENT NUMBER: 136:291358

TITLE: Diagnostic uses of 2-substituted adenosine carboxamides

INVENTOR(S): Leung, Edward

PATENT ASSIGNEE(S): King Pharmaceuticals Research and Development, Inc., USA

SOURCE: U.S., 17 pp.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6368573	B1	20020409	US 1999-440330	19991115
PRIORITY APPLN. INFO.:			US 1999-440330	19991115
OTHER SOURCE(S): MARPAT 136:291358				

AB The invention concerns a method for measuring myocardial function in a mammal in need of such measurement by: (a) administering 2-substituted adenosine carboxamide derivs. at a dosage rate of less than 1 .mu.g/kg/min, preferably between about 0.01 and 1 .mu.g/kg/min; and then: (b) performing a technique on the mammal to detect myocardial function. The method can be used to diagnose myocardial dysfunction by electrophysiol. anal. or by imaging the vasculature of the heart, esp. under conditions that simulate stress.

IT 120225-76-5

RL: ADV (Adverse effect, including toxicity); DGN (Diagnostic use); BIOL (Biological study); USES (Uses)


(diagnostic uses of 2-substituted adenosine carboxamides)

RN 120225-76-5 HCAPLUS

CN Benzenepropanoic acid, 4-[2-[[6-amino-9-[N-ethyl-2,3-O-(1-methylethylidene)-.beta.-D-ribofuranuronamidosyl]-9H-purin-2-yl]amino]ethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

— OBU-t

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L29 ANSWER 3 OF 39 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2001:904207 HCAPLUS

DOCUMENT NUMBER: 136:37902

TITLE: Preparation of 2-aminocarbonyl-9H-purine nucleosides and their uses in treatment of respiratory disease, as A2a receptor agonists and anti-inflammatory agents

INVENTOR(S): Mantell, Simon John; Stephenson, Peter Thomas

PATENT ASSIGNEE(S): Pfizer Limited, UK; Pfizer Inc.

SOURCE: PCT Int. Appl., 198 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001094368	A1	20011213	WO 2001-IB973	20010605
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT,				



RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US,  
 UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,  
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,  
 BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG  
 US 2002058641 A1 20020516 US 2001-874007 20010605  
 EP 1292604 A1 20030319 EP 2001-934242 20010605  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR  
 PRIORITY APPLN. INFO.: GB 2000-14048 A 20000606  
 GB 2000-18246 A 20000725  
 GB 2000-24920 A 20001011  
 US 2000-214307P P 20000627  
 US 2000-225236P P 20000815  
 US 2000-245243P P 20001102  
 WO 2001-IB973 W 20010605  
 OTHER SOURCE(S): MARPAT 136:37902  
 GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB 2-Aminocarbonyl-9H-purine nucleosides I wherein R, R2 are independently H, alkyl; R1 is H, substituted alkyl, fluorenyl; R3 is H, alkyl, cycloalkyl, benzyl; R4 is substituted azetidin-3-yl, pyrrolidin-3-yl, piperidin-3-yl, piperidin-4-yl, homopiperidin-3-yl or homopiperidin-4-yl; R3R4 taken together with the nitrogen atom to which they are attached, represent azetidiny, pyrrolidinyl, piperidinyl, piperazinyl, homopiperidinyl or homopiperazinyl, each being optionally substituted on a ring nitrogen or carbon atom by alkyl or cycloalkyl; R5 is CH2OH, amide; X is substituted alkylene; RX or R2X with the nitrogen atom to which they are attached, represent azetidin-3-yl, pyrrolidin-3-yl, piperidin-3-yl, piperidin-4-yl, homopiperidin-3-yl or homopiperidin-4-yl; Y is CO, CS, SO2, C=N(CN); were prepd. as A2a receptor agonists and anti-inflammatory agents. Thus, nucleoside II was prepd. and tested as A2a receptor agonist and anti-inflammatory agent. Title compds. were tested for biol. activity as A2a receptor agonists and anti-inflammatory agents and all were found to have an IC50 of less than 100 nM.

IT 380222-88-8P 380222-90-2P 380222-92-4P  
 380222-93-5P 380222-94-6P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of 2-aminocarbonyl-9H-purine nucleosides and uses in treatment of respiratory disease, as A2a receptor agonists and anti-inflammatory agents)

RN 380222-88-8 HCAPLUS

CN 9H-Purine-2-carboxylic acid, 6-[(2,2-diphenylethyl)amino]-9-[2,3-O-(1-methylethylidene)-.beta.-D-ribofuranosyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 380222-90-2 HCAPLUS

CN .beta.-D-Ribofuranuronic acid, 1-deoxy-1-[6-[(2,2-diphenylethyl)amino]-2-(ethoxycarbonyl)-9H-purin-9-yl]-2,3-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 380222-92-4 HCAPLUS

CN 9H-Purine-2-carboxylic acid, 6-[(2,2-diphenylethyl)amino]-9-[N-ethyl-2,3-O-(1-methylethylidene)-.beta.-D-ribofuranuronamidosyl]-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 380222-93-5 HCAPLUS

CN 9H-Purine-2-carboxylic acid, 6-[(2,2-diphenylethyl)amino]-9-[N-ethyl-2,3-O-(1-methylethylidene)-.beta.-D-ribofuranuronamidosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 380222-94-6 HCAPLUS


CN .beta.-D-Ribofuranuronamide, 1-deoxy-1-[6-[(2,2-diphenylethyl)amino]-2-[[[2-[[[1-(2-pyridinyl)-4-piperidinyl]amino]carbonyl]amino]ethyl]amino]carbonyl]-9H-purin-9-yl]-N-ethyl-2,3-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L29 ANSWER 4 OF 39 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 2000:911265 HCAPLUS

DOCUMENT NUMBER: 134:66148

TITLE: Induction of pharmacological stress with alkynyladenosine A2A adenosine receptor agonists

INVENTOR(S): Linden, Joel M.; Glover, David K.; Beller, George A.; MacDonald, Timothy

PATENT ASSIGNEE(S): University of Virginia Patent Foundation, USA

SOURCE: PCT Int. Appl., 36 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000078774	A2	20001228	WO 2000-US16029	20000612
WO 2000078774	A3	20010712		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
BR 2000011725	A	20020326	BR 2000-11725	20000612
EP 1194440	A2	20020410	EP 2000-941335	20000612
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2003502433	T2	20030121	JP 2001-504939	20000612
NO 2001005974	A	20020214	NO 2001-5974	20011206

## PRIORITY APPLN. INFO.:

US 1999-336198 A 19990618

WO 2000-US16029 W 20000612

## OTHER SOURCE(S): MARPAT 134:66148

AB A method is provided employing alkynyladenosine A2A adenosine receptor agonists as **vasodilators** to detect the presence and assess the severity of coronary artery stenosis. Prepn. of alkynyladenosine derivs. is also described.

## IT 141018-25-9P 141018-26-0P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. and reaction; alkynyladenosine A2A adenosine receptor agonist for induction of pharmacol. stress and diagnosis of coronary artery stenosis)

RN 141018-25-9 HCAPLUS

CN Adenosine, 2-iodo-2',3'-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 141018-26-0 HCAPLUS

CN .beta.-D-Ribofuranuronic acid, 1-(6-amino-2-iodo-9H-purin-9-yl)-1-deoxy-2,3-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L29 ANSWER 5 OF 39 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1998:34074 HCAPLUS

DOCUMENT NUMBER: 128:188277

TITLE: Adenosine receptor agonists: synthesis and biological evaluation of the diastereoisomers of 2-(3-hydroxy-3-phenyl-1-propyn-1-yl)NECA

AUTHOR(S): Camaioni, Emidio; Di Francesco, Emanuela; Vittori, Sauro; Volpini, Rosaria; Cristalli, Gloria

CORPORATE SOURCE: Dipartimento di Scienze Chimiche, Universita di Camerino, Camerino, 62032, Italy

SOURCE: Bioorganic & Medicinal Chemistry (1997), 5(12), 2267-2275  
CODEN: BMECEP; ISSN: 0968-0896

PUBLISHER: Elsevier Science Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Among the recently reported 2-(ar)alkynyl derivs. of 5'-N-ethylcarboxamidoadenosine (NECA), the (R,S)-2-(3-hydroxy-3-phenyl-1-propyn-1-yl)NECA [(R,S)-PHPNECA or SCH 59761] was found to be a very potent agonist at A1 and A2A receptor subtypes, with a Ki of 2.5 nM and 0.9 nM, resp. Furthermore, this compd. showed an inhibitory activity on platelet aggregation 16-fold higher than NECA, being the most potent anti-aggregatory nucleoside reported so far. Since this compd. bears a chiral carbon in the side chain, the diastereoisomer sepn. was undertaken both by chiral HPLC and by a stereospecific synthetic method. Binding assays have shown that the (S)-diastereomer is about fivefold more potent and selective than the (R)-diastereomer as agonist of the A2A receptor subtype [(S)-PHPNECA, KiA2A = 0.5 nM; (R)-PHPNECA, KiA2A = 2.6 nM]. Functional studies indicated that (S)-PHPNECA possesses marked **vasodilating** activity and produces a relevant decrease in heart rate. Moreover, the (S)-diastereomer proved to be about ten times more potent than the (R)-diastereomer in inducing cardiovascular effects, in vivo hemodynamic studies. However, the greatest difference between these two enantiomers resulted in the platelet aggregation test: in fact, the (R)-diastereomer displayed an inhibitory activity similar to that of NECA, whereas the (S)-diastereomer was 37-fold more active than NECA as an inhibitor of rabbit platelet aggregation, induced by ADP. These data suggest that (S)-PHPNECA could be a useful tool to investigate the mode of binding of agonists to the platelet adenosine receptor subtype.


IT 203794-22-3P 203794-23-4P  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)  
(synthesis and biol. evaluation of diastereoisomers of 2-(3-hydroxy-3-phenyl-1-propyn-1-yl)NECA as adenosine receptor agonists)

RN 203794-22-3 HCAPLUS


CN .beta.-D-Ribofuranuronamide, 1-[6-amino-2-[(3S)-3-[[[(1R)-1-(1-naphthalenyl)ethyl]amino]carbonyl]oxy]-3-phenyl-1-propynyl]-9H-purin-9-yl]-1-deoxy-N-ethyl-2,3-O-(1-methylethylidene)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 203794-23-4 HCAPLUS


CN .beta.-D-Ribofuranuronamide, 1-[6-amino-2-[(3R)-3-[[[[(1R)-1-(1-naphthalenyl)ethyl]amino]carbonyl]oxy]-3-phenyl-1-propynyl]-9H-purin-9-yl]-1-deoxy-N-ethyl-2,3-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



PAGE 1-B



PAGE 1-B




IT 162936-24-5

RL: RCT (Reactant); RACT (Reactant or reagent)  
 (synthesis and biol. evaluation of diastereoisomers of  
 2-(3-hydroxy-3-phenyl-1-propyn-1-yl)NECA as adenosine receptor  
 agonists)

RN 162936-24-5 HCAPLUS

CN .beta.-D-Ribofuranuronamide, 1-(6-amino-2-iodo-9H-purin-9-yl)-1-deoxy-N-ethyl-2,3-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 203794-21-2P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (synthesis and biol. evaluation of diastereoisomers of  
 2-(3-hydroxy-3-phenyl-1-propyn-1-yl)NECA as adenosine receptor  
 agonists)

RN 203794-21-2 HCAPLUS

CN .beta.-D-Ribofuranuronamide, 1-[6-amino-2-(3-hydroxy-3-phenyl-1-propynyl)-9H-purin-9-yl]-1-deoxy-N-ethyl-2,3-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





REFERENCE COUNT: 27 THERE ARE 27 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L29 ANSWER 6 OF 39 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1997:761605 HCAPLUS

DOCUMENT NUMBER: 128:34983

TITLE: Preparation of nucleosides as A3 adenosine receptor agonists

INVENTOR(S): Jacobson, Kenneth A.; Jeong, Heaok Kim; Siddiqi, Suhaib M.; Johnson, Carl R.; Secrist, John A., III; Tiwari, Kamal N.

PATENT ASSIGNEE(S): United States Dept. of Health and Human Services, USA  
SOURCE: U.S., 35 pp., Cont.-in-part of U.S. Ser. No. 274,628.  
CODEN: USXXAM

DOCUMENT TYPE: Patent



LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5688774	A	19971118	US 1995-396111	19950228
US 5773423	A	19980630	US 1994-274628	19940713
PRIORITY APPLN. INFO.:			US 1993-91109	B2 19930713
			US 1993-163324	B2 19931206
			US 1994-274628	A2 19940713

OTHER SOURCE(S): MARPAT 128:34983  
GI



AB Title nucleosides I (R = H, Y; R1 = benzyl, halobenzyl; R2 = H, halo, alkylamino; X1 = H, alkyl; X2 = alkylamido; X3, X4 = independently H, OH,

NH<sub>2</sub>, N<sub>3</sub>, halo, Bz) were prepd. as A<sub>3</sub> adenosine receptor agonists. The present invention also provides a method of selectively activating an A<sub>3</sub> adenosine receptor in a mammal, which method comprises acutely or chronically administering to a mammal in need of selective activation of its A<sub>3</sub> adenosine receptor a therapeutically or **prophylactically** effective amt. of a compd. which binds with the A<sub>3</sub> receptor so as to stimulate an A<sub>3</sub> receptor-dependent response. Thus, N<sub>3</sub>-(3-iodobenzyl)-9-Me adenine was prepd. and showed an affinity at rat brain adenosine receptors ( $K_i = 2.23-48.3 \text{ } \mu\text{M}$ ).


IT 163042-89-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of nucleosides as a adenosine receptor agonists)

RN 163042-89-5 HCAPLUS

CN .beta.-D-Ribofuranuronamide, 1-[2-chloro-6-[[ (3-iodophenyl)methyl]amino]-9H-purin-9-yl]-1-deoxy-N-methyl-, cyclic 2,3-carbonothioate (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 170966-20-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(prepn. of nucleosides as a adenosine receptor agonists)

RN 170966-20-8 HCAPLUS

CN .beta.-D-Ribofuranuronamide, 1-[6-[[ (3-aminophenyl)methyl]amino]-9H-purin-9-yl]-1-deoxy-N-methyl-2,3-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L29 ANSWER 7 OF 39 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1997:12370 HCAPLUS

DOCUMENT NUMBER: 126:75189

TITLE: Preparation of N6-(phenylalkyl)adenosine derivatives having selective affinity to adenosine A3 receptor

INVENTOR(S): Mitsuya, Morihiro; Takeshita, Hiroshi; Ihara, Masaki

PATENT ASSIGNEE(S): Banyu Pharma Co Ltd, Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 12 pp.

CODEN: JKXXAF


DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 08269083	A2	19961015	JP 1995-101772	19950403
PRIORITY APPLN. INFO.:			JP 1995-101772	19950403
OTHER SOURCE(S):			MARPAT 126:75189	
GI				



I

AB The title compds. (I; Ar = Ph, arom. heterocyclyl; Q = lower alkylene; R1 = Cl, lower alkyl, alkoxy, or alkylthio, NR4R5; wherein R4, R5 = H, lower alkyl; R2 = HOCH2, H2NCO, N-alkylcarbamoyl; R3 = H, OH, NH2, lower alkoxy) or pharmaceutically acceptable salts thereof, which have reduced side effects, are prepd. A remedy for **hypertension**, unstable angina pectoris, acute myocardial infarction, and/or brain nerve disorders contg. I is claimed. Thus, 1-(2,6-dichloro-9H-purin-9-yl)-2,3-O-isopropylidene-.beta.-D-ribofuranuronic acid (prepn. given) was condensed with 3-(2-thiazolyl)benzylamine hydrochloride (prepn. given) in EtOH at room temp. for 15 h and then with methylamine using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride in CHCl3, followed by treatment with aq. 85% HCO2H, to give the title compd. (II). II showed Ki (competitive binding inhibition const.) of 6,990 and 1.00 for adenosine A1 receptor prepn. from rat homogenized brain and adenosine A3 receptor of Rat basophilic leukemia mast cells (RBL-2H3), resp.

IT 184847-93-6P 184847-94-7P 184847-95-8P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of N6-(phenylalkyl)adenosine derivs. having selective affinity to adenosine A3 receptor for disease treatment)

RN 184847-93-6 HCAPLUS

CN .beta.-D-Ribofuranuronamide, 1-[2-chloro-6-[[[3-(2-thiazolyl)phenyl]methyl]amino]-9H-purin-9-yl]-1-deoxy-N-methyl-2,3-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 184847-94-7 HCAPLUS

CN .beta.-D-Ribofuranuronic acid, 1-[2-chloro-6-[[[3-(2-thiazolyl)phenyl]methyl]amino]-9H-purin-9-yl]-1-deoxy-2,3-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 184847-95-8 HCAPLUS

CN .beta.-D-Ribofuranuronamide, 1-deoxy-N-methyl-1-[2-(methylamino)-6-[[[3-(2-thiazolyl)phenyl]methyl]amino]-9H-purin-9-yl]-2,3-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L29 ANSWER 8 OF 39 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1996:616599 HCAPLUS

DOCUMENT NUMBER: 125:317355

TITLE: Preparation of adenosine derivatives having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties

INVENTOR(S): Spada, Alfred P.; Fink, Cynthia A.; Myers, Michael R.

PATENT ASSIGNEE(S): Rhone-Poulenc Rorer Pharmaceuticals Inc., USA

SOURCE: U.S., 27 pp., Cont.-in-part of U. S. Ser. No. 229,882, abandoned.

CODEN: USXXAM

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 6

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5561134	A	19961001	US 1994-316761	19941003
US 5364862	A	19941115	US 1992-955783	19921002
CA 2188147	AA	19951026	CA 1995-2188147	19950419
CA 2188147	C	20010403		
WO 9528160	A1	19951026	WO 1995-US4800	19950419
W: AM, AT, AU, BB, BG, BR, BY, CA, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TT, UA, UG				
RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9522949	A1	19951110	AU 1995-22949	19950419

AU 684635	B2	19971218		
EP 758897	A1	19970226	EP 1995-916451	19950419
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
CN 1148811	A	19970430	CN 1995-193170	19950419
CN 1086704	B	20020626		
HU 75331	A2	19970528	HU 1996-2829	19950419
BR 9507327	A	19971007	BR 1995-7327	19950419
JP 09512020	T2	19971202	JP 1995-527171	19950419
EP 1006115	A2	20000607	EP 2000-103467	19950419
EP 1006115	A3	20000628		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE				
RU 2166319	C2	20010510	RU 1996-121567	19950419
NZ 284357	A	20010629	NZ 1995-284357	19950419
CZ 289528	B6	20020213	CZ 1996-3032	19950419
PL 182942	B1	20020531	PL 1995-316961	19950419
US 5736554	A	19980407	US 1995-455361	19950531
US 5652366	A	19970729	US 1995-484811	19950607
NO 9604438	A	19961018	NO 1996-4438	19961018
FI 9604218	A	19961217	FI 1996-4218	19961018
CZ 290897	B6	20021113	CZ 2001-2885	20010808
PRIORITY APPLN. INFO.:			US 1990-587884	B2 19900925
			US 1992-955783	A2 19921002
			US 1994-229882	B2 19940419
			US 1994-316761	A 19941003
			CZ 1996-3032	A3 19950419
			EP 1995-916451	A3 19950419
			WO 1995-US4800	W 19950419
OTHER SOURCE(S):			MARPAT 125:317355	
GI				



AB The adenosine derivs. I [K = N or NO; Q = CH<sub>2</sub> or O; T = R<sub>1</sub>R<sub>2</sub>NCO or R<sub>3</sub>OCH<sub>2</sub>; X = (un)substituted alkylene, cycloalkylene or cycloalkenylene Y = NR<sub>4</sub>, O or S; a = 0 or 1; Z = substituted pyrrolyl, pyrazolyl, indolyl, etc.; R<sub>1</sub>-5 = H, alkyl, aryl or heterocyclyl; R<sub>5</sub>, R<sub>6</sub> = H, alkyl, aralkyl, etc.] are prepd. as antihypertensive, cardioprotective, antiischemic, and antilipolytic agents.

IT 165115-09-3P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT


(Reactant or reagent)

(intermediate in prepn. of adenosine deriv. drug)

RN 165115-09-3 HCAPLUS

CN .beta.-D-Ribofuranuronamide, 1-deoxy-N-ethyl-2,3-O-(1-methylethylidene)-1-[6-[[6-(2-thienyl)-3-cyclohexen-1-yl]amino]-9H-purin-9-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L29 ANSWER 9 OF 39 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1995:997439 HCAPLUS

DOCUMENT NUMBER: 124:202956

TITLE: Preparation of adenosine derivatives having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties.

INVENTOR(S): Spada, Alfred P.; Fink, Cynthia A.; Myers, Michael R.

PATENT ASSIGNEE(S): Rhone-Poulenc Rorer Pharmaceuticals Inc., USA

SOURCE: PCT Int. Appl., 75 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English




FAMILY ACC. NUM. COUNT: 6

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9528160	A1	19951026	WO 1995-US4800	19950419
W: AM, AT, AU, BB, BG, BR, BY, CA, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TT, UA, UG				
RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 5561134	A	19961001	US 1994-316761	19941003
AU 9522949	A1	19951110	AU 1995-22949	19950419
AU 684635	B2	19971218		



EP 758897	A1	19970226	EP 1995-916451	19950419
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
BR 9507327	A	19971007	BR 1995-7327	19950419
JP 09512020	T2	19971202	JP 1995-527171	19950419
RU 2166319	C2	20010510	RU 1996-121567	19950419
NZ 284357	A	20010629	NZ 1995-284357	19950419
PL 182942	B1	20020531	PL 1995-316961	19950419
NO 9604438	A	19961018	NO 1996-4438	19961018
FI 9604218	A	19961217	FI 1996-4218	19961018
PRIORITY APPLN. INFO.:			US 1994-229882	A 19940419
			US 1994-316761	A 19941003
			US 1990-587884	B2 19900925
			US 1992-955783	A2 19921002
			WO 1995-US4800	W 19950419
OTHER SOURCE(S):			MARPAT 124:202956	
GI				



AB Title compds. [I; K = N, NO, CH; Q = CH<sub>2</sub>, O; T = R<sub>3</sub>R<sub>4</sub>NCO, R<sub>5</sub>OCH<sub>2</sub>; X = (substituted) alkylene, cycloalkylene, cycloalkenylene; Y = NR<sub>6</sub>, O, S; a = 0, 1; R<sub>1</sub>, R<sub>2</sub> = H, alkyl, aralkyl, carbamoyl, acyl, alkoxycarbonyl, aralkoxycarbonyl, aryloxycarbonyl; R<sub>1</sub>R<sub>2</sub> = CO, CS, etc.; R<sub>3</sub>-R<sub>8</sub> = H, alkyl, aryl, heterocyclyl; Z = Q<sub>1</sub>, Q<sub>2</sub>; Z<sub>1</sub> = N, CR<sub>7</sub>, (CH)<sub>m</sub>C<sub>5</sub>, (CH)<sub>m</sub>N; m = 1, 2; Z<sub>2</sub> = N, NR<sub>8</sub>, O, S; n = 0, 1; R<sub>9</sub>, R<sub>10</sub> = H, OH, alkyl, hydroxyalkyl, alkylmercapto, thioalkyl, alkoxy, amino, acyl, halo, carbamoyl, etc.], were prepd. Thus, trans-2-(2-thienyl)cyclohex-4-enylamine, 6-chloropurine, and Et<sub>3</sub>N were refluxed in EtOH to give N<sup>6</sup>-[trans-2-(2-thienyl)-cyclohex-4-enyl]adenosine. The latter bound to adenosine A<sub>1</sub> and A<sub>2</sub> receptors with IC<sub>50</sub> = 1.66 nM and 55 nM, resp., and induced vasorelaxation in swine coronary artery with IC<sub>50</sub> = 0.73 .mu.M.

IT 173935-07-4P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of adenosine derivs. having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties)

RN 173935-07-4 HCAPLUS

CN .beta.-D-Ribofuranuronamide, 1-deoxy-N-ethyl-2,3-O-(1-methylethylidene)-1-[6-[[6-(2-thienyl)-3-cyclohexen-1-yl]amino]-9H-purin-9-yl]-, (1S-trans)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



L29 ANSWER 10 OF 39 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1995:837438 HCAPLUS

DOCUMENT NUMBER: 123:257265

TITLE: Preparation of N6-benzyladenosine-5'-uronamides, modified xanthine ribosides, and related compounds as adenosine A3 receptor agonists.

INVENTOR(S): Jacobson, Kenneth A.; Gallo-Rodriguez, Carola; Von Galen, Philip J. M.; Von Lubitz, Dag K. J. E.; Jeong, Heaok Kim

PATENT ASSIGNEE(S): United States Dept. of Health and Human Services, USA

SOURCE: PCT Int. Appl., 175 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9502604	A1	19950126	WO 1994-US7835	19940713
W: AU, CA, JP				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9473310	A1	19950213	AU 1994-73310	19940713
EP 708781	A1	19960501	EP 1994-923445	19940713
EP 708781	B1	20011004		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE  
 AT 206432 E 20011015 AT 1994-923445 19940713  
 PRIORITY APPLN. INFO.: US 1993-91109 A 19930713  
 US 1993-163324 A 19931206  
 WO 1994-US7835 W 19940713  
 OTHER SOURCE(S): MARPAT 123:257265  
 GI




AB Title compds. [I; R1 = RaRbNCO, HORc; Ra, Rb = H, alkyl, amino, haloalkyl, aminoalkyl, cycloalkyl, BOC-aminoalkyl; RaRbN = heterocyclyl; Rc = alkyl, amino, haloalkyl, aminoalkyl, cycloalkyl, BOC-aminoalkyl; R2 = H, halo, alkyl ether residue, amino, alkylamino, alkenyl, alkynyl, thio, alkylthio; R3 = (R)- and (S)-1-phenylethyl, (substituted) PhCH2, substituted phenylethyl] and related compds., were prepd. Thus, 2-chloro-N6-(3-iodobenzyl)adenine was refluxed with hexamethyldisilazane and cat. (NH4)2SO4 to give a silyl deriv. which was refluxed with N-Me I-O-acetyl-2,3-dibenzoyl-.alpha.,.beta.-D-ribofuronamide and trimethylsilyl triflate in dichloroethane to give 2-chloro-N6-(3-iodobenzyl)-9-[5-(methylamido)-2,3-di-O-benzoyl-.beta.-D-ribofuranosyl]adenine. The latter was stirred with NH3 in MeOH for 16 h to give 68.7% 2-chloro-N6-(3-iodobenzyl)-9-[5-(methylamido)-.beta.-D-ribofuranosyl]adenine. This showed Ki = 0.23 nM in a radioligand binding assay at rat brain A3 receptors.

IT 362-75-4, 2',3'-Isopropylideneadenosine  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (prepn. of N6-benzyladenosine-5'-uronamides, modified xanthine ribosides, and related compds. as adenosine A3 receptor agonists)

RN 362-75-4 HCAPLUS  
 CN Adenosine, 2',3'-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 19234-66-3P 23754-29-2P 152918-54-2P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of N6-benzyladenosine-5'-uronamides, modified xanthine ribosides, and related compds. as adenosine A3 receptor agonists)

RN 19234-66-3 HCAPLUS

CN .beta.-D-Ribofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-1-deoxy-2,3-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 23754-29-2 HCAPLUS

CN .beta.-D-Ribofuranuronic acid, 1-(6-amino-9H-purin-9-yl)-1-deoxy-2,3-O-(1-methylethylidene)-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 152918-54-2 HCAPLUS

CN Benzenesulfonic acid, 4-[[[9-[N-methyl-2,3-O-(1-methylethylidene)-.beta.-D-ribofuranuronamidosyl]-9H-purin-6-yl]amino]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L29 ANSWER 11 OF 39 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1995:508300 HCAPLUS

DOCUMENT NUMBER: 122:291434

TITLE: 2-Aralkynyl and 2-Heteroalkynyl Derivatives of Adenosine-5'-N-Ethyluronamide as Selective A2a Adenosine Receptor Agonists

AUTHOR(S): Cristalli, Gloria; Camaioni, Emidio; Vittori, Sauro; Volpini, Rosaria; Borea, Pier Andrea; Conti, Annamaria; Dionisotti, Silvio; Ongini, Ennio; Monopoli, Angela

CORPORATE SOURCE: Dipartimento di Scienze Chimiche, Universita di Camerino, Camerino, 62032, Italy

SOURCE: Journal of Medicinal Chemistry (1995), 38(9), 1462-72  
CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society


DOCUMENT TYPE:

Journal

LANGUAGE:

English

GI



AB A series of new 2-alkynyl and 2-heteroalkynyl derivs. of 5'-(N-carboxamido)adenosine NECA, e.g. I [R = H, Ph, C<sub>6</sub>H<sub>4</sub>R<sub>1</sub>-4, 2-pyridyl, 2-furyl, 2-thiazolyl; R<sub>1</sub> = Me, OMe, OH, NH<sub>2</sub>, F], were synthesized and studied in binding and functional assays to assess their potency for the A<sub>2a</sub> compared to A<sub>1</sub> adenosine receptors. Compds. bearing an arom. or heteroarom. ring, conjugated to the triple bond, showed generally weaker activity at the A<sub>2a</sub> receptor and lower selectivity (A<sub>2a</sub> vs A<sub>1</sub>) than the alkylalkynyl derivs. previously reported. However, the (4-formylphenyl)ethynyl deriv. showed affinity in the low nanomolar range and high selectivity (about 160-fold) for the A<sub>2a</sub> receptor. The presence of heteroatoms improved vasorelaxant activity, I (R = 2-thiazolyl) being the most potent in the series. Introduction of methylene groups between the triple bond and the Ph ring favored the A<sub>2a</sub> binding affinity, and the 5-phenyl-1-pentynyl deriv. was found to be highly potent and selective (about 180-fold) at A<sub>2a</sub> receptors. With regard to platelet activity, the presence of arom. or heteroarom. rings decreased the potency in comparison with that of NECA and of N-ethyl-1'-deoxy-1'-(6-amino-2-hexynyl-9H-purin-9-yl)-.beta.-D-ribofuranuronamide (HNECA). Introduction of a methylene group was effective in increasing antiaggregatory potency only when this group is linked to a heteroatom. From these data and those previously reported, the structure-activity relationships derived for the 2-alkynyl-substituted ribose uronamides would indicate that selective potentiation of A<sub>2a</sub> receptor affinity could be obtained by arom. rings not conjugated with the triple bond or by heteroarom. groups. As for A<sub>2a</sub> receptors on platelets, the presence of arom. rings, either conjugated or unconjugated to the triple bond, is detrimental for the antiaggregatory activity. Some of the compds. included in this series retain interesting **vasodilating** properties and merit further investigation for their potential in the treatment of cardiovascular disorders.

IT 141018-26-0

RL: RCT (Reactant); RACT (Reactant or reagent)


(prepn. of aralkynyl and heteroalkynyl derivs. of carboxamidoadenosine as selective A<sub>2a</sub> adenosine receptor agonists)

RN 141018-26-0 HCAPLUS

CN .beta.-D-Ribofuranuronic acid, 1-(6-amino-2-iodo-9H-purin-9-yl)-1-deoxy-

2,3-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 162936-24-5P 162936-39-2P 162936-40-5P

162936-41-6P 162936-42-7P 162936-43-8P

162936-44-9P 162936-45-0P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of aralkynyl and heteroalkynyl derivs. of carboxamidoadenosine as selective A2a adenosine receptor agonists)

RN 162936-24-5 HCAPLUS

CN .beta.-D-Ribofuranuronamide, 1-(6-amino-2-iodo-9H-purin-9-yl)-1-deoxy-N-ethyl-2,3-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 162936-39-2 HCAPLUS

CN Benzenepropanoic acid, 4-[[6-amino-9-[N-ethyl-2,3-O-(1-methylethylidene)-.beta.-D-ribofuranuronamidosyl]-9H-purin-2-yl]ethynyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 162936-40-5 HCAPLUS

CN .beta.-D-Ribofuranuronamide, 1-[6-amino-2-(5-phenyl-1-pentynyl)-9H-purin-9-yl]-1-deoxy-N-ethyl-2,3-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 162936-41-6 HCAPLUS

CN .beta.-D-Ribofuranuronamide, 1-[6-amino-2-[3-(1H-imidazol-1-yl)-1-propynyl]-9H-purin-9-yl]-1-deoxy-N-ethyl-2,3-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 162936-42-7 HCAPLUS

CN .beta.-D-Ribofuranuronamide, 1-[6-amino-2-[3-(1-piperidiny)-1-propynyl]-9H-purin-9-yl]-1-deoxy-N-ethyl-2,3-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 162936-43-8 HCAPLUS

CN .beta.-D-Ribofuranuronamide, 1-[6-amino-2-[3-(4-methyl-1-piperazinyl)-1-propynyl]-9H-purin-9-yl]-1-deoxy-N-ethyl-2,3-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 162936-44-9 HCAPLUS

CN .beta.-D-Ribofuranuronamide, 1-[6-amino-2-[3-(4-morpholinyl)-1-propynyl]-9H-purin-9-yl]-1-deoxy-N-ethyl-2,3-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 162936-45-0 HCAPLUS

CN .beta.-D-Ribofuranuronamide, 1-[6-amino-2-[3-(4-thiomorpholinyl)-1-propynyl]-9H-purin-9-yl]-1-deoxy-N-ethyl-2,3-O-(1-methylethylidene)- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.



L29 ANSWER 12 OF 39 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1995:346678 HCAPLUS

DOCUMENT NUMBER: 122:106395

TITLE: preparation of adenosine sulfohydrocarbon radicals for treatment of ischemia or hypoxia in mammals

INVENTOR(S): Jacobson, Kenneth A.; Maillard, Michel C.

PATENT ASSIGNEE(S): United States Dept. of Health and Human Services, USA

SOURCE: PCT Int. Appl., 42 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9402497	A1	19940203	WO 1993-US6590	19930713
W: AU, CA, JP				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				

AU 9347724      A1    19940214      AU 1993-47724      19930713  
 US 5498605      A     19960312      US 1994-278704      19940721  
 PRIORITY APPLN. INFO.:      US 1992-914428      A    19920715  
    WO 1993-US6590      W    19930713  
 OTHER SOURCE(S):      MARPAT 122:106395  
 GI



AB The adenosine derivs., e.g. I, wherein at least one of R1-R6 is a sulfohydrocarbon radical, the remaining R groups are non-sulfohydrocarbon radicals, and W is -OCH2-, -NHCH2-, -SCH2-, or -NH(CO)-. Thus, 6-chloropurine riboside reacted with sulfonylamine in BuOH and NEt3 gave N6-p-sulfophenyladenosine. Methods of prep. such compds., as well as methods of using such compds. to treat **ischemia** or hypoxia in mammals and pharmaceutical compns. contg. such compds. as the active ingredients, are also described. Binding of I with A1 and A2 adenosine receptors at rat brain is reported.

IT 3250-02-0


RL: RCT (Reactant); RACT (Reactant or reagent)


(reaction of, in prepn. of adenosine sulfohydrocarbon radicals)

RN 3250-02-0 HCAPLUS

CN Adenosine, 2',3'-O-(ethoxymethylene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





L29 ANSWER 13 OF 39 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1995:261298 HCAPLUS

DOCUMENT NUMBER: 123:228787

TITLE: Preparation of adenosine analogs as antihypertensives and antiischemics.

INVENTOR(S): Spada, Alfred P.; Fink, Cynthia A.; Myers, Michael R.

PATENT ASSIGNEE(S): Rhone-Poulenc Rorer Pharmaceuticals Inc., USA

SOURCE: U.S., 25 pp. Cont.-in-part of U.S. Ser. No. 587,884, abandoned.

CODEN: USXXAM

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 6


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5364862	A	19941115	US 1992-955783	19921002
CA 2092305	AA	19920326	CA 1991-2092305	19910925
AT 147074	E	19970115	AT 1991-917927	19910925
ES 2095960	T3	19970301	ES 1991-917927	19910925
SG 80526	A1	20010522	SG 1996-3118	19910925
US 5561134	A	19961001	US 1994-316761	19941003
US 5736554	A	19980407	US 1995-455361	19950531
US 5652366	A	19970729	US 1995-484811	19950607
PRIORITY APPLN. INFO.:			US 1990-587884	B2 19900925
			US 1992-955783	A2 19921002
			US 1994-229882	B2 19940419
			US 1994-316761	A1 19941003

OTHER SOURCE(S): MARPAT 123:228787  
GI



I



AB Title compds. [I; K = N, NO, CH; Q = CH<sub>2</sub>, O; T = R<sub>2</sub>, R<sub>1</sub>R<sub>2</sub>NCO, R<sub>3</sub>OCH<sub>2</sub>; X = alkylene, cycloalkylene, cycloalkenylene; Y = NR<sub>4</sub>, O, S; a = 0, 1; Z = Q<sub>1</sub>, Q<sub>2</sub>; Z<sub>1</sub> = N, CR<sub>5</sub>, (CH)<sub>m</sub>CR<sub>5</sub>, (CH)<sub>m</sub>N; m = 1, 2; Z<sub>2</sub> = N, NR<sub>6</sub>, O, S; n = 0, 1; R<sub>1</sub>-R<sub>6</sub> = H, alkyl, aryl, heterocyclyl; R<sub>a</sub>, R<sub>b</sub> = H, OH, alkyl, hydroxyalkyl, alkylmercaptyl, thioalkyl, alkoxy, alkoxyalkyl amino, alkylamino, carboxyl, acyl halo, carbamoyl, alkylcarbamoyl, aryl, heterocyclyl; R', R'' = H, alkyl, aralkyl, carbamoyl, alkylcarbamoyl, dialkylcarbamoyl, acyl, alkoxy carbonyl, aralkoxy carbonyl, aryloxy carbonyl; R'R'' = CO, CS, CHOR<sub>c</sub>, CR<sub>d</sub>Re; R<sub>c</sub>, R<sub>d</sub>, R<sub>e</sub> = H, alkyl; R<sub>d</sub>Re = atoms to form a cycloalkyl ring; with provisos), were prepd. Thus, N<sup>6</sup>-[trans-2-(thiophen-2-yl)cyclohex-1-yl]adenosine, prepd. from 6-chloropurine riboside and the corresponding amine, at 5 mg/kg orally in rats reduced mean arterial blood pressure and heart rate by 45% and 22%, resp.

IT 165115-09-3P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of adenosine analogs as antihypertensives and antiischemics)

RN 165115-09-3 HCAPLUS

CN .beta.-D-Ribofuranuronamide, 1-deoxy-N-ethyl-2,3-O-(1-methylethylidene)-1-[6-[[6-(2-thienyl)-3-cyclohexen-1-yl]amino]-9H-purin-9-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L29 ANSWER 14 OF 39 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1994:621999 HCAPLUS

DOCUMENT NUMBER: 121:221999

TITLE: Preparation of adenosine kinase-inhibiting purine nucleoside analogs as antiinflammatory agents

INVENTOR(S): Firestein, Gary Steven; Ugarkar, Bheemarao Ganapatrao; Miller, Leonard Paul; Gruber, Harry Edward; Bullough, David Andrew; Erion, Mark David; Castellino, Angelo John

PATENT ASSIGNEE(S): Gensia, Inc., USA

SOURCE: PCT Int. Appl., 114 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 14

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9417803	A1	19940818	WO 1994-US1340	19940203
W: AT, AU, BB, BG, BR, CA, CH, CN, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, UZ				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9462365	A1	19940829	AU 1994-62365	19940203
EP 682519	A1	19951122	EP 1994-909558	19940203
R: CH, DE, FR, GB, IT, LI				
US 5646128	A	19970708	US 1994-349125	19941201
PRIORITY APPLN. INFO.:				
		US 1993-14190	A	19930203
		US 1989-408707	B2	19890915
		US 1990-466979	B2	19900118
		US 1991-647117	B2	19910123
		US 1991-812916	B2	19911223
		US 1994-192645	B1	19940203
		WO 1994-US1340	W	19940203
OTHER SOURCE(S):		MARPAT 121:221999		

GI



AB Novel nucleosides I [A = O, CH<sub>2</sub>, S; B' = (CH<sub>2</sub>)<sub>n</sub>B, alkenyl, alkynyl; B = H, alkyl, alkoxy, NH<sub>2</sub>, alkylamino, etc.; C1, C2 = H, acyl, hydrocarbyloxycarbonyl, or C1C2 = C(:O), .alpha.-alkoxyalkylidene; X = CD; D = H, halo, alkyl, cyano, CO<sub>2</sub>H, etc.; Y = N, CE; E = H, halo, alkyl, alkylthio; F = alkyl, aryl, halo, cyano, indolyl, pyrrolidinyl, etc.; G = H, halo, alkyl, alkoxy, alkylamino, alkylthio; n = 1-4], prep'd. by multistep procedures which are described, selectively inhibit adenosine kinase and are useful in treatment of conditions characterized by an inflammatory response. Such conditions include sepsis, arthritis, autoimmune disease, burns, psoriasis, conjunctivitis, etc. Thus, mice with endotoxemia resulting from injection of *Escherichia coli* lipopolysaccharide showed a dose-dependent increase in survival in response to i.v. injection of the adenosine kinase inhibitor, 4-amino-1-(5-amino-5-deoxy-1-.beta.-D-ribofuranosyl)-3-bromopyrazolo[3,4-d]pyrimidine-HCl; this effect was antagonized by the adenosine receptor antagonist 8-(p-sulphophenyl)theophylline.

IT 20789-78-0 21950-36-7


RL: RCT (Reactant); RACT (Reactant or reagent)

(prepn. of adenosine kinase-inhibiting purine nucleoside analogs as antiinflammatory agents)

RN 20789-78-0 HCAPLUS

CN Adenosine, 8-bromo-2',3'-O-(1-methylethylidene)-, 5'-(4-methylbenzenesulfonate) (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 21950-36-7 HCAPLUS

CN Adenosine, 5'-amino-5'-deoxy-2',3'-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT 144927-45-7P 158077-68-0P 158077-70-4P

158077-71-5P 158077-74-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(prepn. of adenosine kinase-inhibiting purine nucleoside analogs as antiinflammatory agents)

RN 144927-45-7 HCAPLUS

CN Adenosine, 8-bromo-N-formyl-2',3'-O-(1-methylethylidene)-, 5'-(4-methylbenzenesulfonate) (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 158077-68-0 HCAPLUS

CN Adenosine, 5',8-diazido-5'-deoxy-2',3'-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 158077-70-4 HCAPLUS

CN 9H-Purine, 6-(2,3-dihydro-1H-indol-1-yl)-9-[2,3-O-(1-methylethylidene)-.beta.-D-ribofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 158077-71-5 HCAPLUS

CN 9H-Purine, 6-(2,3-dihydro-1H-indol-1-yl)-9-[2,3-O-(1-methylethylidene)-5-O-[(4-methylphenyl)sulfonyl]-.beta.-D-ribofuranosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 158077-74-8 HCAPLUS

CN Adenosine, 5',8-diazido-5'-deoxy-N-formyl-2',3'-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L29 ANSWER 15 OF 39 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1993:496074 HCAPLUS

DOCUMENT NUMBER: 119:96074

TITLE: Preparation of adenosine derivatives as cardiovascular agents.

INVENTOR(S): Matsuda, Akira; Azebiru, Toichi; Yamaguchi, Toyofumi; Watanabe, Yoko; Miyashita, Takanori

PATENT ASSIGNEE(S): Yamasa Shoyu Co., Ltd., Japan

SOURCE: Jpn. Kokai Tokkyo Koho, 29 pp.

CODEN: JKXXAF

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 05025195	A2	19930202	JP 1991-202598	19910717
JP 3025559	B2	20000327		

PRIORITY APPLN. INFO.: JP 1990-191285 A1 19900719

JP 1990-218690 A1 19900820

OTHER SOURCE(S): MARPAT 119:96074

GI



I

AB The title compds. [I; R1 = (un)substituted carbamoyl, CO2H,

alkoxycarbonyl, CH<sub>2</sub>-N<sub>3</sub>, (un)substituted aminomethyl, etc.; R<sub>2</sub> = (hydroxy)alkyl], useful for treatment of brain ischemia, heart ischemia, and hypertension, are prepd. E.g., 2-iodoadenosine was condensed with acetone, the resulting 2',3'-O-isopropylidene deriv. in MeCN-CHCl<sub>3</sub> was oxidized with K periodate in H<sub>2</sub>O, the product was esterified with MeOH, the resulting Me ester was treated with methanolic NH<sub>3</sub>, the resulting carboxamide was heated with 1-hexyne in DMF contg. Pd(PPh<sub>3</sub>)<sub>2</sub>, CuCl, and Et<sub>3</sub>N, and the resulting 2-(1-hexynyl)-2',3'-isopropylideneadenosine-4'-carboxamide was deprotected to give 2-(1-hexynyl)-adenosine-4'-carboxamide, which had an ED<sub>50</sub> of 0.13 .mu.g/Kg in spontaneously hypertensive mice.


IT 142102-95-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(prepn. of, as cardiovascular agent)

RN 142102-95-2 HCAPLUS

CN Adenosine, 5'-deoxy-2-(1-hexynyl)-5'-[[ (methylamino)thioxomethyl]amino]-2',3'-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 141018-25-9P 141018-26-0P 142102-84-9P  
142102-85-0P 142102-86-1P 142102-87-2P  
142102-90-7P 142102-91-8P 142102-92-9P  
142102-93-0P 142102-94-1P 142103-01-3P  
142103-03-5P 142103-04-6P 149037-59-2P  
149037-60-5P 149037-61-6P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. of, as intermediate for cardiovascular agents)

RN 141018-25-9 HCAPLUS

CN Adenosine, 2-iodo-2',3'-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 141018-26-0 HCAPLUS

CN .beta.-D-Ribofuranuronic acid, 1-(6-amino-2-iodo-9H-purin-9-yl)-1-deoxy-2,3-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 142102-84-9 HCAPLUS

CN .beta.-D-Ribofuranuronic acid, 1-(6-amino-2-iodo-9H-purin-9-yl)-1-deoxy-2,3-O-(1-methylethylidene)-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 142102-85-0 HCAPLUS

CN .beta.-D-Ribofuranuronic acid, 1-[6-amino-2-(1-hexynyl)-9H-purin-9-yl]-1-deoxy-2,3-O-(1-methylethylidene)-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 142102-86-1 HCAPLUS

CN Adenosine, 2-(1-hexynyl)-2',3'-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 142102-87-2 HCAPLUS

CN Adenosine, 5'-azido-5'-deoxy-2-(1-hexynyl)-2',3'-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 142102-90-7 HCAPLUS

CN Adenosine, 5'-amino-5'-deoxy-2-(1-hexynyl)-2',3'-O-(1-methylethylidene)-  
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 142102-91-8 HCAPLUS

CN Adenosine, 5'-deoxy-5'-(formylamino)-2-(1-hexynyl)-2',3'-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 142102-92-9 HCAPLUS

CN Adenosine, 5'-(acetylamino)-5'-deoxy-2-(1-hexynyl)-2',3'-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 142102-93-0 HCAPLUS

CN Adenosine, 5'-deoxy-2-(1-hexynyl)-2',3'-O-(1-methylethylidene)-5'-[(methylsulfonyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 142102-94-1 HCAPLUS

CN Adenosine, 5'-deoxy-2-(1-hexynyl)-5'-[[ (methylamino)carbonyl]amino]-2',3'-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 142103-01-3 HCAPLUS

CN .beta.-D-Ribofuranuronamide, 1-[6-amino-2-(1-hexynyl)-9H-purin-9-yl]-1-deoxy-2,3-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 142103-03-5 HCAPLUS

CN .beta.-D-Ribofuranuronamide, 1-[6-amino-2-(1-hexynyl)-9H-purin-9-yl]-1-deoxy-N-ethyl-2,3-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 142103-04-6 HCAPLUS

CN .beta.-D-Ribofuranuronamide, 1-[6-amino-2-(1-hexynyl)-9H-purin-9-yl]-N-cyclopropyl-1-deoxy-2,3-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 149037-59-2 HCAPLUS

CN .beta.-D-Ribofuranuronamide, 1-(6-amino-2-iodo-9H-purin-9-yl)-1-deoxy-2,3-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 149037-60-5 HCAPLUS

CN .beta.-D-Ribofuranuronic acid, 1-[6-amino-2-(3-hydroxy-1-propynyl)-9H-purin-9-yl]-1-deoxy-2,3-O-(1-methylethylidene)-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 149037-61-6 HCAPLUS

CN .beta.-D-Ribofuranuronamide, 1-[6-amino-2-(3-hydroxy-1-propynyl)-9H-purin-9-yl]-1-deoxy-2,3-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L29 ANSWER 16 OF 39 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1993:234420 HCAPLUS

DOCUMENT NUMBER: 118:234420

TITLE: Adenosine kinase inhibitors

INVENTOR(S): Browne, Clinton E.; Ugarkar, Bheemarao G.; Mullane, Kevin M.; Gruber, Harry E.; Bullough, David A.; Erion, Mark D.; Castellino, Angelo

PATENT ASSIGNEE(S): Gensia Pharmaceuticals, Inc., USA

SOURCE: Eur. Pat. Appl., 87 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 14

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 496617	A1	19920729	EP 1992-300580	19920123
EP 496617	B1	19991201		


R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, PT, SE

CA 2100863	AA 19920724	CA 1992-2100863	19920121
WO 9212718	A1 19920806	WO 1992-US515	19920121
W: AU, CA, FI, NO			
AU 665184	B2 19951221	AU 1992-13599	19920121
AU 9213599	A1 19920827		
JP 05112595	A2 19930507	JP 1992-10094	19920123
IL 100742	A1 19960618	IL 1992-100742	19920123
AT 187175	E 19991215	AT 1992-300580	19920123
NO 9302628	A 19930923	NO 1993-2628	19930721
NO 180418	B 19970106		
NO 180418	C 19970416		
US 5646128	A 19970708	US 1994-349125	19941201

PRIORITY APPLN. INFO.:

US 1991-647117	A 19910123
US 1991-812916	A 19911223
US 1989-408707	B2 19890915
US 1990-466979	B2 19900118
WO 1992-US515	W 19920121
US 1993-14190	B2 19930203
US 1994-192645	B1 19940203

OTHER SOURCE(S): MARPAT 118:234420  
GI



AB Nucleoside analogs I [A = O, CH<sub>2</sub>, S; B = (un)substituted C1-4 alkyl; C, Cl = H, protective group(s); X = (un)substituted CH; Y = N, (un)substituted CH; F = alkyl, aryl, aralkyl, halogen, (un)substituted NH<sub>2</sub>, substituted OH or SH, cyano, cyanoalkyl; G = H, halogen, alkyl, alkoxy, alkylamino, alkylthio] were prepd. Thus, the analog II was prepd. from the pyrimidinone via the azide. II has an adenosine kinase-inhibiting ED<sub>50</sub> of <10 nM and was effective in improving post-ischemic functional recovery in isolated guinea pig heart and in preclin. angina models.


IT 21950-36-7

RL: RCT (Reactant); RACT (Reactant or reagent)  
(formylation of)

RN 21950-36-7 HCAPLUS

CN Adenosine, 5'-amino-5'-deoxy-2',3'-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




IT 144927-50-4P 144927-52-6P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(prepn. and deisopropylidenation of)

RN 144927-50-4 HCAPLUS

CN Adenosine, 5'-deoxy-5'-(formylamino)-2',3'-O-(1-methylethylidene)- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 144927-52-6 HCAPLUS

CN 9H-Purine, 9-[2,3-O-(1-methylethylidene)-5-O-[(4-methylphenyl)sulfonyl]-  
.beta.-D-ribofuranosyl]-6-(octahydro-1H-indol-1-yl)- (9CI) (CA INDEX  
NAME)

Absolute stereochemistry.




IT 144927-45-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(prepn. and reaction of, with azide)

RN 144927-45-7 HCAPLUS

CN Adenosine, 8-bromo-N-formyl-2',3'-O-(1-methylethylidene)-,  
5'-(4-methylbenzenesulfonate) (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 144927-51-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(prepn. and tosylation of)

RN 144927-51-5 HCAPLUS

CN 9H-Purine, 9-[2,3-O-(1-methylethylidene)-.beta.-D-ribofuranosyl]-6-  
(octahydro-1H-indol-1-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L29 ANSWER 17 OF 39 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1992:470205 HCAPLUS

DOCUMENT NUMBER: 117:70205

TITLE: Nucleosides and nucleotides. 112.

2-(1-Hexyn-1-yl)adenosine-5'-uronamides: a new entry  
of selective A2 adenosine receptor agonists with  
potent antihypertensive activity

AUTHOR(S): Homma, Hiroshi; Watanabe, Yohko; Abiru, Toichi;  
Murayama, Toshihiko; Nomura, Yasuharu; Matsuda, Akira

CORPORATE SOURCE: Fac. Pharm. Sci., Hokkaido Univ., Sapporo, 060, Japan


SOURCE: Journal of Medicinal Chemistry (1992), 35(15), 2881-90

CODEN: JMCMAR; ISSN: 0022-2623

DOCUMENT TYPE: Journal

LANGUAGE: English


GI



- AB Chem. modifications of the potent A2 adenosine receptor agonist 2-(hexynyl)adenosine I (R = R<sup>1</sup>, R<sup>2</sup> = OH) (II) at the 5'-position have been carried out to find more potent and selective A2 agonists. These analogs were evaluated for adenosine A1 and A2 receptor binding affinity in rat brain tissues and antihypertensive effects in spontaneously hypertensive rats (SHR). Among the series of compds., I (R = R<sup>3</sup>, R<sup>4</sup> = cyclopropyl) had the most potent affinity to the A2 receptor with a K<sub>i</sub> of 2.6 nM, which is essentially the same as that of the parent agonist II. However, the most selective agonist for the A2 receptor was 2-(1-hexyn-1-yl)adenosine-5'-N-methyluronamide I (R = R<sup>3</sup>, R<sup>4</sup> = Me) with a K<sub>i</sub> of 11 nM and a 162-fold selectivity. Therefore, the A1/A2 selectivity was consequently increased. Other 5'-deoxy-5'-substituted derivs., e.g. I [R = R<sup>1</sup>, R<sup>2</sup> = Cl (III); R = R<sup>3</sup>, R<sup>4</sup> = H, Me, NHMe), were also prepd. Among these nucleosides, no active compds. with potent or selective affinities to both receptors were found except III. Although glycosyl conformations and sugar-puckering of these nucleosides were studied by 1H NMR spectroscopy, there were no pos. correlations between active and inactive agonists. I (R = R<sup>3</sup>, R<sup>4</sup> = H, cyclopropyl) had a potent hypotensive effect at ED<sub>30</sub> values of 0.18 and 0.17 .mu.g/kg, resp., upon i.v. administration to anesthetized SHR.
- IT 142102-85-0P 142102-90-7P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (prepn. and amidation of)
- RN 142102-85-0 HCAPLUS
- CN .beta.-D-Ribofuranuronic acid, 1-[6-amino-2-(1-hexynyl)-9H-purin-9-yl]-1-deoxy-2,3-O-(1-methylethylidene)-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 142102-90-7 HCAPLUS

CN Adenosine, 5'-amino-5'-deoxy-2-(1-hexynyl)-2',3'-O-(1-methylethylidene)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 142102-86-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(prepn. and azidolysis of)

RN 142102-86-1 HCAPLUS

CN Adenosine, 2-(1-hexynyl)-2',3'-O-(1-methylethylidene)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

**IT 142102-84-9P**


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. and coupling of, with hexyne)

RN 142102-84-9 HCAPLUS

CN .beta.-D-Ribofuranuronic acid, 1-(6-amino-2-iodo-9H-purin-9-yl)-1-deoxy-2,3-O-(1-methylethylidene)-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

**IT 142102-91-8P 142102-92-9P 142102-93-0P**

**142102-94-1P 142102-95-2P**


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. and deblocking of)

RN 142102-91-8 HCAPLUS

CN Adenosine, 5'-deoxy-5'-(formylamino)-2-(1-hexynyl)-2',3'-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 142102-92-9 HCAPLUS

CN Adenosine, 5'-(acetylamino)-5'-deoxy-2-(1-hexynyl)-2',3'-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 142102-93-0 HCAPLUS

CN Adenosine, 5'-deoxy-2-(1-hexynyl)-2',3'-O-(1-methylethylidene)-5'-[(methylsulfonyl)amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 142102-94-1 HCAPLUS

CN Adenosine, 5'-deoxy-2-(1-hexynyl)-5'-[[ (methylamino) carbonyl] amino]-2',3'-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 142102-95-2 HCAPLUS

CN Adenosine, 5'-deoxy-2-(1-hexynyl)-5'-[[ (methylamino) thioxomethyl] amino]-2',3'-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 142102-88-3P 142103-01-3P 142103-02-4P  
 142103-03-5P 142103-04-6P 142103-05-7P  
 142103-06-8P

RL: SPN (Synthetic preparation); PREP (Preparation)  
 (prepn. and deisopropylidene of)

RN 142102-88-3 HCAPLUS

CN Adenosine, 5'-chloro-5'-deoxy-2-(1-hexynyl)-2',3'-O-(1-methylethylidene)-  
 (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 142103-01-3 HCAPLUS

CN .beta.-D-Ribofuranuronamide, 1-[6-amino-2-(1-hexynyl)-9H-purin-9-yl]-1-  
 deoxy-2,3-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 142103-02-4 HCAPLUS

CN .beta.-D-Ribofuranuronamide, 1-[6-amino-2-(1-hexynyl)-9H-purin-9-yl]-1-deoxy-N-methyl-2,3-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 142103-03-5 HCAPLUS

CN .beta.-D-Ribofuranuronamide, 1-[6-amino-2-(1-hexynyl)-9H-purin-9-yl]-1-deoxy-N-ethyl-2,3-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 142103-04-6 HCAPLUS

CN .beta.-D-Ribofuranuronamide, 1-[6-amino-2-(1-hexynyl)-9H-purin-9-yl]-N-cyclopropyl-1-deoxy-2,3-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 142103-05-7 HCAPLUS

CN .beta.-D-Ribofuranuronamide, 1-[6-amino-2-(1-hexynyl)-9H-purin-9-yl]-1-deoxy-2,3-O-(1-methylethylidene)-N-propyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 142103-06-8 HCAPLUS

CN .beta.-D-Ribofuranuronamide, 1-[6-amino-2-(1-hexynyl)-9H-purin-9-yl]-N-butyl-1-deoxy-2,3-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 141018-26-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(prepn. and esterification of)

RN 141018-26-0 HCAPLUS

CN .beta.-D-Ribofuranuronic acid, 1-(6-amino-2-iodo-9H-purin-9-yl)-1-deoxy-2,3-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 142102-87-2P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(prepn., chlorination, and redn. of)

RN 142102-87-2 HCAPLUS

CN Adenosine, 5'-azido-5'-deoxy-2-(1-hexynyl)-2',3'-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






IT 141018-25-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(prepn., oxidn., and coupling of, with hexyne)

RN 141018-25-9 HCAPLUS

CN Adenosine, 2-iodo-2',3'-O-(1-methylethylidene)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L29 ANSWER 18 OF 39 HCAPLUS COPYRIGHT 2003 ACS

ACCESSION NUMBER: 1992:236101 HCAPLUS

DOCUMENT NUMBER: 116:236101

TITLE: Preparation of new adenosine derivatives as  
cardiovascular agents.

INVENTOR(S): Gadiant, Fulvio

PATENT ASSIGNEE(S): Sandoz-Patent-G.m.b.H., Germany

SOURCE: Ger. Offen., 8 pp.

CODEN: GWXXBX

DOCUMENT TYPE: Patent


LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 4025879	A1	19920220	DE 1990-4025879	19900816

CA 2064869	AA 19920217	CA 1991-2064869	19910813
WO 9203463	A1 19920305	WO 1991-CH170	19910813
W: AU, CA, CS, FI, HU, JP, KR, PL, SU, US			
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE			
AU 9183032	A1 19920317	AU 1991-83032	19910813
AU 638600	B2 19930701		
EP 496852	A1 19920805	EP 1991-913964	19910813
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE			
HU 60504	A2 19920928	HU 1992-1080	19910813
JP 05502889	T2 19930520	JP 1991-513113	19910813
ZA 9109267	A 19930524	ZA 1991-9267	19911212
RO 110236	B1 19951130	RO 1992-152	19920213
PRIORITY APPLN. INFO.:		DE 1990-4025879	A 19900816
		WO 1991-CH170	A 19910813
OTHER SOURCE(S):		MARPAT 116:236101	
GI			




- AB The title compds. [I; R1 = H, alkyl, cycloalkyl, Ph, (substituted) phenylalkyl; R2 = H, alkyl, halo, cycloalkyl; R3 = CH2OH, CONHR4; R4 = H, alkyl, cycloalkyl; X = O, S], useful for the treatment of hypertension, thrombolism, supraventricular tachycardia, etc. (no data), were prepd. Cyclocondensation of 1'-deoxy-1'-(6-p-methoxyanilino-2-methyl-9-puriny)-.beta.-D-ribofuranuronic acid N-ethylamide with 1,1'-carbonyldi-1H-imidazole in DMF at room temp. for 5 h gave I [R1 = p-MeOC6H4, R2 = Me, R3 = EtNHCO, X = O].
- IT 141426-21-3P 141426-22-4P 141426-23-5P  
 141426-24-6P 141426-25-7P 141426-26-8P  
 141426-27-9P 141426-28-0P 141426-29-1P  
 141426-30-4P 141426-31-5P 141426-32-6P  
 141426-33-7P 141426-34-8P 141426-35-9P  
 141426-36-0P 141426-37-1P 141426-38-2P  
 141426-39-3P 141426-40-6P 141426-41-7P  
 141426-42-8P 141426-43-9P 141448-37-5P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of, as cardiovascular agent)

RN 141426-21-3 HCAPLUS

CN .beta.-D-Ribofuranuronamide, 1-deoxy-N-ethyl-1-[6-[(4-methoxyphenyl)amino]-2-methyl-9H-purin-9-yl]-, cyclic 2,3-carbonate (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 141426-22-4 HCAPLUS

CN Adenosine, N-cyclohexyl-, cyclic 2',3'-carbonate (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 141426-23-5 HCAPLUS

CN .beta.-D-Ribofuranuronamide, 1-[6-(cyclopentylamino)-2-methyl-9H-purin-9-yl]-1-deoxy-N-ethyl-, cyclic 2,3-carbonate (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 141426-24-6 HCAPLUS

CN .beta.-D-Ribofuranuronamide, 1-[6-(cyclopentylamino)-9H-purin-9-yl]-1-deoxy-N-ethyl-, cyclic 2,3-carbonate (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 141426-25-7 HCAPLUS

CN .beta.-D-Ribofuranuronamide, 1-[6-(cyclohexylamino)-9H-purin-9-yl]-1-deoxy-N-ethyl-, cyclic 2,3-carbonate (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 141426-26-8 HCAPLUS

CN .beta.-D-Ribofuranuronamide, 1-deoxy-N-ethyl-1-[6-[(4-methoxyphenyl)amino]-9H-purin-9-yl]-, cyclic 2,3-carbonate (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 141426-27-9 HCAPLUS

CN .beta.-D-Ribofuranuronamide, 1-deoxy-N-ethyl-1-[6-(phenylamino)-9H-purin-9-yl]-, cyclic 2,3-carbonate (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 141426-28-0 HCAPLUS

CN .beta.-D-Ribofuranuronamide, 1-deoxy-N-ethyl-1-[6-[(4-fluorophenyl)amino]-9H-purin-9-yl]-, cyclic 2,3-carbonate (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 141426-29-1 HCAPLUS

CN .beta.-D-Ribofuranuronamide, 1-[6-[(4-chlorophenyl)amino]-9H-purin-9-yl]-1-deoxy-N-ethyl-, cyclic 2,3-carbonate (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 141426-30-4 HCAPLUS

CN .beta.-D-Ribofuranuronamide, 1-[6-(cyclohexylamino)-2-methyl-9H-purin-9-yl]-1-deoxy-N-ethyl-, cyclic 2,3-carbonate (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 141426-31-5 HCAPLUS

CN .beta.-D-Ribofuranuronamide, 1-deoxy-N-ethyl-1-[2-methyl-6-[(1-methylethyl)amino]-9H-purin-9-yl]-, cyclic 2,3-carbonate (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 141426-32-6 HCAPLUS

CN .beta.-D-Ribofuranuronamide, 1-deoxy-N-ethyl-1-[2-methyl-6-(phenylamino)-9H-purin-9-yl]-, cyclic 2,3-carbonate (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 141426-33-7 HCAPLUS

CN .beta.-D-Ribofuranuronamide, 1-deoxy-N-ethyl-1-[6-[(4-fluorophenyl)amino]-2-methyl-9H-purin-9-yl]-, cyclic 2,3-carbonate (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 141426-34-8 HCAPLUS

CN .beta.-D-Ribofuranuronamide, 1-[6-[(4-chlorophenyl)amino]-2-methyl-9H-purin-9-yl]-1-deoxy-N-ethyl-, cyclic 2,3-carbonate (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 141426-35-9 HCAPLUS

CN .beta.-D-Ribofuranuronamide, 1-deoxy-N-ethyl-1-[6-[(4-methoxyphenyl)amino]-2-methyl-9H-purin-9-yl]-, cyclic 2,3-carbonothioate (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 141426-36-0 HCAPLUS

CN .beta.-D-Ribofuranuronamide, 1-(6-amino-2-methyl-9H-purin-9-yl)-1-deoxy-N-ethyl-, cyclic 2,3-carbonate (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 141426-37-1 HCAPLUS

CN .beta.-D-Ribofuranuronamide, 1-deoxy-N-ethyl-1-[6-[(4-methoxyphenyl)amino]-9H-purin-9-yl]-, cyclic 2,3-carbonothioate (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 141426-38-2 HCAPLUS

CN .beta.-D-Ribofuranuronamide, 1-[6-[(4-chlorophenyl)amino]-2-methyl-9H-purin-9-yl]-1-deoxy-N-ethyl-, cyclic 2,3-carbonothioate (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 141426-39-3 HCAPLUS


CN .beta.-D-Ribofuranuronamide, 1-deoxy-N-ethyl-1-[6-[(4-fluorophenyl)amino]-2-methyl-9H-purin-9-yl]-, cyclic 2,3-carbonothioate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 141426-40-6 HCAPLUS  
 CN Adenosine, N-(4-methoxyphenyl)-, cyclic 2',3'-carbonate (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 141426-41-7 HCAPLUS  
 CN Adenosine, N-(4-chlorophenyl)-, cyclic 2',3'-carbonate (9CI) (CA INDEX NAME)

Absolute stereochemistry.